Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: Modulation by oxidation and vitamin E

Blood

Volumn 91, Issue 2, 1998, Pages 508-515

  Rota, Simin ^a   McWilliam, Nicola A ^a   Baglin, Trevor P ^a   Byrne, Christopher D ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BLOOD CLOTTING FACTOR 10A; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; THROMBIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; FEMALE; HUMAN; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBIN TIME;

EID: 0031962759     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.2.508     Document Type: Article

References (46)

1. Miller GJ: Lipoproteins and the haemostatic system inatherothrombotic disorders. Bailliere's Clin Haematol 7:713, 1994
2. Fager G: Thrombin and proliferation of vascular smooth muscle cells. Circ Res 77:645, 1995
3. Wenzel UO, Fouqueray B, Grandaliano G, Kin YS, Karamitsos C, Valente AJ, Abboud HE: Thrombin regulates expression of monocyte chemoattractant protein-1 in vascular smooth muscle cells. Circ Res 77:503. 1995
4. Li X-N, Varma VK, Parks JM, Benza RL, Koons JC, Grammer JR, Grenett H, Tabengwa EM, Booyse FM: Thrombin decreases the urokinase receptor and surface-localized fibrinolysis in cultured endothelial cells. Arterioscler Thromb Vasc Biol 15:410, 1995
5. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR; Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 90:1614, 1992
6. Wilcox JN, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong C, Hayzer BJ, Horaist C, Hanson SR, Lumsden A, Salam TA, Kelly AB, Harker LA, Runge M: Characterization of thrombin receptor expression during vascular lesion formation. Circ Res 75:1029, 1994
7. McVey JH: Tissue factor pathway. Bailliere's Clin Haematol 7:469,1994
8. Papahadjopoulos D, Hanahan DJ: Observations on the interaction of phospholipids and certain clotting factors in prothrombin activator formation. Biochem Biophys Acta 90:436, 1964
9. Hemker HC, Esnouf MP, Hemker PW, Swart ACW, MacFarlane RG: Formation of the prothrombin converting activity. Nature 215:248, 1967
10. Govers-Riemslag JW, Janssen MP, Zwaal RF, Rosing J: Prothrombin activation on dioleoylphosphatidylcholine membranes. Eur J Biochem 220:131, 1994
11. Bradley WA, Song JN, Gianturco SH: Thrombin/prothrombin interactions with very low density lipoproteins. Ann NY Acad Sci 485:159, 1986
12. Bradley WA, Gianturco SH: Vitamin K-dependent proteins bind to very low-density lipoproteins. Semin Thromb Hemost 14:253, 1988
13. Bajaj SP, Harmony JAK, Martinez-Carrion M, Castellino FJ: Human plasma lipoproteins as accelerators of prothrombin activation. J Biol Chem 251:5233, 1976
14. Davi G, Ganci A, Averna M, Giammarresi C, Barbagallo C, Catalano I, Cala A, Notarbatolo A: Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia. Thromb Haemost 74:1015, 1995
15. Broijersen A, Hamsten A, Silveira A, Fatah K, Goodall AJ, Eriksson M, Angelin B, Hjemdahl P: Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. Thromb Haemost 76:171, 1996
16. 1+2 concentration, a marker of coagulability in patients with coronary heart disease. Thromb Haemost 67:503, 1992
17. Bröijersén A, Eriksson M, Leijd B, Angelin B, Hjemdahl P: No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 17:273, 1997
18. Yokode M, Hammer RE, Ishibashi S, Brown MS, Goldstein JL: Diet-induced hypercholesterolaemia in mice-prevention by overexpression of LDLreceptors. Science 250:1273, 1990
19. Schacterle GR, Pollack RL; A simplified method for the quantitative assay of small amounts of protein in biologic material. Anal Biochem 51:654, 1973
20. Byrne CD, Wang TWM, Hales CN: Control of Hep G2-cell triacylglycerol and apolipoprotein B synthesis and secretion by polyunsaturated non-esterified fatty acids and insulin. Biochem J 288:101, 1992
21. Hemker HC, Béguin S: Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 74:134, 1995
22. Lee LH, Baglin T: Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis. Brit J Haematol 89:131, 1995
23. Vecchini A, Chiaradia E, Covalovo S, Binaglia L: Quantitation of phospholipids on thin layer Chromatographic plates using a desk-top scanner. Mol Cell Biol 145:25, 1995
24. Hoff HF, Whitaker TE, O'Neil J: Oxidation of low density lipoprotein leads to particle aggregation and altered macrophage recognition. J Biol Chem 264:602, 1992
25. Wallin B, Rosengren B, Shertzer HG, Camejo G: Lipoprotein oxidation and measurement of thiobarbituric acid reacting substances formation in a single microtitre plate: its use for evaluation of antioxidants. Anal Biochem 208:10, 1993
26. Lyons TJ, Li W, WellsKnecht MC, Jokl R: Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes 43:1090, 1994
27. Pigault C, Folleniuswund A, Schmutz M, Freyssinet JM, Brisson A: Formation of two-dimensional arrays of annexin V on phosphatidy1-serine-containing liposomes. J Mol Biol 236:199, 1994
28. Andree HAM, Reutelingsperger CPM, Hauptmann R, Hemker HC, Hermens WT, Willems GM: Binding of vascular anticoagulant alpha (VACalpha) to planar phospolipid bilayers. J Biol Chem 265: 4293, 1990
29. Meers P, Daleke D, Hong K, Papahadjopoulos D: Interactions of annexins with membrane phospholipids. Biochemistry 30:2903, 1991
30. Meers P, Mealy T: Phospholipid determinants for annexin V binding sites and the role of tryptophan 187. Biochemistry 33:5829, 1994
31. Steinberg D, Parathasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: Modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 320:915, 1989
32. Witztum JL: The oxidation hypothesis of atherosclerosis. Lancet 344:793, 1994
33. Rapp JH, Lespine A. Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, Kotite L, Kunitake ST, Havel RJ, Kane JP: Triglyceride-rich lipoproteins isolated by selected-affinity anti apolipo-protein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 14:1767, 1994
34. Nordestgaard, BG, Wooton R, Lewis B: Selective retention of VLDL, IDL and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo, molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol 15:534, 1995
35. Assman G, Schulte H, von Eckardstein A: Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 77:1179, 1996
36. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213, 1996
37. Billy D, Willems GM, Hemker HC, Lindhout T: Prothrombin contributes to the assembly of the factor Va-factor Xa complex at phosphatidylserine-containing phospholipid membranes. J Biol Chem 270:26883, 1995
38. Hubbard AR, Jennings CA. Inhibition of the tissue factor-factor VII complex: Involvement of factor Xa and lipoproteins. Thromb Res 46:527, 1987
39. Sandset PM, Bendz B. Tissue factor pathway inhibitor: Clinical deficiency states. Thromb Haemost 78:467, 1997
40. Bruckdorfer KR: Oxidized lipoproteins. Bailliere's Clin Endocrinol Metab 9:721, 1995
41. Femandez-Ortiz A, Badimon J, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L: Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol 23:1562, 1994
42. Pentikäinen MO, Lehtonen EMP, Kovanen PT: Aggregation and fusion of modified low density lipoprotein. J Lipid Res 37:2638, 1996
43. Jessup W, Rankin SM, de Whalley CV, Hoult JRS, Scott J, Leake DS: Alpha-tocopherol consumption during low-density lipoprotein oxidation. Biochem J 265:399, 1990
44. Rimm ER, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC: Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328:1450, 1993
45. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC: Vitamin E consumption and the risk of coronary heart disease in women. N Engl J Med 328:1444, 1993
46. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, Brown MJ: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347:781, 1996